DAS
BTAI icon

Diversify Advisory Services’s BioXcel Therapeutics BTAI Stock Holding History

Diversify Advisory Services’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13K Buy
+15,000
New +$17.6K ﹤0.01% 1249

Other funds holding BTAI

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Diversify Advisory Services's BTAI Position: Q2 2026 in Review

Diversify Advisory Services opened a new position in BioXcel Therapeutics (BTAI) in Q2 2026: 15,000 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #1249 among its holdings.

32 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Diversify Advisory Services held 15,000 shares of BioXcel Therapeutics worth $13K as of Q2 2026.
  • BioXcel Therapeutics was a new Diversify Advisory Services position in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Diversify Advisory Services's portfolio in Q2 2026, its #1249 holding.
  • 32 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Diversify Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.